Predictors of repeat transarterial chemoembolization in the treatment of hepatocellular carcinoma. Issue 12 (26th August 2014)

• Record Type: Journal Article
• Authors: White, Jared A.; Redden, David T.; Bryant, Mary Kate; Dorn, David; Saddekni, Souheil; Aal, Ahmed Kamel Abdel; Zarzour, Jessica; Bolus, David; Smith, J. Kevin; Gray, Stephen; Eckhoff, Devin E.; DuBay, Derek A.
• Is Part Of: HPB. Volume 16:Issue 12(2014:Dec.)
• Page Start: 1095
• Page End: 1101
• Publication Date: 2014-08-26
• Subjects: Liver -- Diseases -- Periodicals; Biliary tract -- Diseases -- Periodicals; Pancreas -- Diseases -- Periodicals; 616.362005
• DOI: 10.1111/hpb.12313
• Languages: English
• ISSNs: 1365-182X

Abstract

Abstract: Objectives: Repeat transarterial chemoembolization (TACE) is a common intervention performed for hepatocellular carcinoma (HCC). The aim of this study was to identify predictors of the need for repeat TACE. Methods: Between 2008 and 2012, data on patient and tumour variables were collected for 262 patients treated with a first TACE procedure for HCC. The decision to perform repeat TACE procedures was made at the completion of the first TACE or after follow‐up imaging demonstrated the subtotal treatment of HCC tumours. Results: Repeat TACE was performed in 67 of 262 (25.6%) patients. Necrosis of HCC, measured after the first TACE, was lower in patients who subsequently received repeat TACE ( P = 0.042). On multivariable analysis, total tumour diameter of >5 cm [odds ratio (OR) 2.76, 95% confidence interval (CI) 1.45–5.25; P = 0.002] and increasing age (OR 1.04/year, 95% CI 1.00–1.07; P = 0.030) were predictive of the need for repeat TACE. Measures of liver function and TACE approach (selective versus non‐selective) were not predictive of repeat TACE. Median survival did not differ significantly between patients who did (median survival: 21.1 months) and did not (median survival: 26.1 months) receive a repeat TACE procedure ( P = 0.574). Conclusions: The requirement for repeat TACE is associated with older age, increased HCC tumour burden and subtotal TACE‐induced HCC necrosis. Importantly, repeat TACE was not associated with reduced survival.